EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT06138834

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06138834
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06138834. Randomized; quadruple masking; primary purpose treatment. Start 2023-11 (anticipated); primary completion 2024-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)
Condition
Acute Ischemic Stroke
Condition
Large Vessel Occlusion
Condition
Reperfusion
Intervention (Drug)
Low-dose Y-6 sublingual tablets
Intervention (Drug)
High-dose Y-6 sublingual tablets
Intervention (Drug)
Low-dose Cilostazol
Intervention (Drug)
High-dose Cilostazol
Intervention (Drug)
Placebo
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Neurodawn Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06138834
Content hash
8a372a70a1a2d087050c2ab16dfa39d31c01da0f70228b09b83e39029d72b0f0